Monopar Therapeutics 3Q 2026: EPS ($0.72) — 10-Q Summary

Monopar Therapeutics reported a widened net loss for 3Q 2026, with increased R&D and administrative expenses. The company began NDA submission for ALXN1840 and expects funds to last until March 2028. Net loss was $6.2M, with diluted EPS at -$0.72.

Original reporting
Published Nov 12, 2026, 1:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 1:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Monopar Therapeutics 3Q 2026: EPS ($0.72) — 10-Q Summary — source image
Decision brief

The 30-second read

$MNPRBearishLow
01

Why it matters

The widened loss and EPS decline suggest short‑term downside, but the ongoing NDA submission and funded runway provide a longer‑term catalyst.

02

Market read

Primary micro‑cap earnings release with modest scale; relevant mainly to biotech and specialty pharma traders.

03

What to watch

The company still has funding secured through 2028, which may cushion short‑term volatility.

Relevance 5/10Novelty 5/10Timing: post‑market today

Background

Monopar Therapeutics (NASDAQ: MNPR) filed its Q3 2026 10‑Q, summarizing financial and operational highlights.

Company-level read

Ticker impact

$MNPRBearishMedium confidence
Context

Monopar Therapeutics reported a widened net loss and lower EPS in its Q3 2026 10‑Q filing.

Expected impact

downward pressure as investors price in the larger loss and higher expenses

Evidence & confidence

Earnings miss and higher R&D spend suggest short‑term downside risk despite ongoing NDA submission.

Market effects

Highlights continued cash burn in the radiopharmaceutical biotech sector.

Limited to U.S. biotech investors; no broader regional effect.

Minimal; the news is company‑specific.

Counterpoint

If the NDA rollout for ALXN1840 succeeds, the long‑term upside could outweigh the near‑term loss.

Key entities

  • Monopar Therapeutics

    Biotech firm developing radiopharmaceuticals, ticker MNPR.

Related articles

$MNPRMed

Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates

Monopar Therapeutics (MNPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates Wilmette, IL, November 12, 2026 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative t

$MNPRMedAI 8/10

Monopar presents Wilson disease trial data at liver conference

Monopar Therapeutics (MNPR) presented Phase 3 FoCus trial data for Wilson disease at a liver conference. Key findings include high rates of cirrhosis, neurologic, and psychiatric symptoms among patients. ALXN1840, its investigational therapy, showed positive long-term data. The trial is the largest randomized controlled study in Wilson disease.

$MNPRMedAI 8/10

Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026

Monopar Therapeutics (MNPR) presented data from its Phase 3 FoCus trial at AASLD 2026, showing significant disease burden in Wilson disease patients, including cirrhosis, neurologic, and psychiatric symptoms. ALXN1840, Monopar's investigational therapy, demonstrated long-term safety with neutral molybdenum balance and normal uric acid levels over six years.

$MNPRLow

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Monopar Therapeutics (MNPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates Wilmette, IL, August 12, 2026 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative tr

$MNPRMedAI 8/10

Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026

Monopar Therapeutics presented Phase 2 ALXN1840 (tiomolibdate choline) data at EASL 2026 for treatment-experienced Wilson disease patients. In an open-label, multicenter 48-week trial (29 patients; 24 with paired biopsies), histology showed stabilization or improvement in multiple liver measures, with no statistically significant change in hepatic copper. The company also reported significant improvements in UWDRS Part III, CGI, and EQ-5D UK, with generally nonserious Grade 1–2 adverse events.